CN103054932A - 楹树提取物在制备治疗胃溃疡药物中的应用 - Google Patents
楹树提取物在制备治疗胃溃疡药物中的应用 Download PDFInfo
- Publication number
- CN103054932A CN103054932A CN2011103263611A CN201110326361A CN103054932A CN 103054932 A CN103054932 A CN 103054932A CN 2011103263611 A CN2011103263611 A CN 2011103263611A CN 201110326361 A CN201110326361 A CN 201110326361A CN 103054932 A CN103054932 A CN 103054932A
- Authority
- CN
- China
- Prior art keywords
- hall
- principal columns
- extract
- preparation
- osbeck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 241001643995 Albizia chinensis Species 0.000 title claims abstract description 23
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 21
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 10
- 208000007882 Gastritis Diseases 0.000 claims abstract description 5
- 208000023652 chronic gastritis Diseases 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 239000002904 solvent Substances 0.000 claims description 15
- 239000004952 Polyamide Substances 0.000 claims description 11
- 229920002647 polyamide Polymers 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 150000001298 alcohols Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 5
- 239000000612 proton pump inhibitor Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 238000012360 testing method Methods 0.000 abstract description 5
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract description 2
- 108010083204 Proton Pumps Proteins 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 11
- -1 micropill Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 241000220433 Albizia Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000011438 Albizia odoratissima Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028103 Mucosa vesicle Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical class CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了楹树提取物在制备治疗胃溃疡药物中的应用。具体而言，本发明公开了一种楹树提取物，这种楹树提取物的制备方法，将干燥的楹树茎皮粉碎、提取、浓缩和纯化制备楹树提取物。含有这种楹树提取物的药物组合物。药理试验结果表明这种楹树提取物对质子泵的活性抑制作用强，可作为治疗胃溃疡、慢性胃炎等酸相关性疾病，其抗胃溃疡效果明显，起效快，安全可靠。
Description
技术领域
本发明涉及一种楹树[Albizia chinensis(Osbeck)Merr.]中提取物及其制备方法，本发明还涉及楹树提取物作为质子泵抑制剂在制备治疗胃溃疡和酸相关性疾病药物中的医药用途，医药技术领域，。
背景技术
胃溃疡是消化系统常见的疾病，且易复发。随着现代生活节奏加快，精神紧张和工作压力增大，使得胃溃疡的发病率呈上升趋势，危害及人们的身心健康。目前临床上应用较多的抗溃疡西药主要为雷尼替丁、奥美拉唑等药物，虽然西药近期疗效明显，但其存在服药后出现不良反应和毒副作用。因此，人们开始研发高效、低毒的新型的抗溃疡药物。基于我国传统中药的长期临床实践和用药历史，从传统中草药中寻找和挖掘具有抗胃溃疡的天然活性成分或有效组分，具有先天优势和广阔的临床应用价值。
楹树Albizia chinensis(Osbeck)Merr.为豆科合欢属(Albizia)植物，其药用部位为树皮，树皮含鞣质，有固涩止泻、收敛生肌之功效，主治肠炎、腹泻、痢疾(全国中草药汇编，全国中草药汇编编写组编，第二版，下册，1986年，PP768)。另有记载楹树皮含三萜皂苷(又称合欢催产素)，有收缩子宫的作用(中药大辞典，江苏新医学院编，1998年，上册，PP937)。近年来，我们从楹树皮中分离得到一系列结构复杂的具有肿瘤细胞毒活性的三萜皂苷(J.Nat.Prod.2009，72，632-639；Carbohydr.Res.2010，345，1877-1881)。此外，我们还发现楹树Albiziachinensis提取物具有镇静催眠的活性(中国专利公开号CN101766676A)。迄今为止尚未见有关楹树皮提取物在抑制质子泵活性和治疗胃溃疡或慢性胃炎方面的药理活性研究的报道。
发明内容
本发明要解决的技术问题是，提供一类新的治疗胃溃疡和酸相关性疾病的药物，即楹树Albizia chinensis(Osbeck)Merr.提取物。本发明的楹树Albizia chinensis(Osbeck)Merr.提取物可作为质子泵抑制剂，用于制备治疗胃溃疡和酸相关性疾病药物。
本发明要解决的另一个技术问题是提供制备楹树提取物的方法以及这种方法获得的楹树提取物。
本发明要解决的又一个技术问题是提供一种药物组合物，包括作为活性成分的楹树提取物及制药领域中常用的载体。
本发明要解决的再一个技术问题是提供楹树提取物Albiziachinensis(Osbeck)Merr.在制备治疗胃溃疡和酸相关性疾病药物中的应用。
解决本发明的技术问题，本发明采取如下的技术方案：
本发明涉及一种可用于制备质子泵抑制剂治疗胃溃疡和酸相关性疾病药物的楹树提取物，其制备方法为：
(1)将楹树原药材粉碎并用溶剂提取，提取液浓缩得楹树浸膏。
优选的楹树原药材是楹树茎皮。楹树原药材经干燥并适当的粉碎，以利增大与溶剂的接触面积提高效率。
原药材的提取溶剂可以使用醇类溶剂或水与醇类的混合溶剂。
优选的醇类包括甲醇、乙醇、异丙醇、丁醇等，最优选的是乙醇。
乙醇浓度可以是体积比50-100％；优选的浓度为体积比80～95％。
提取时溶剂使用量是溶剂体积与原药材重量的体积/重量比(单位：升/公斤)为4～12∶1，优选是8～10∶1。
提取可以在静态或动态下进行，优选在动态条件下，例如搅拌。为了提高提取的效率，可以使用超声波等。
提取的温度是从室温(例如20℃)到溶剂回流温度的范围内，优选的温度是溶剂回流的温度下。
提取可连续或间歇进行，间歇提取时可重复1～5次，优选3-4次。
提取时间是1-5小时，优选为2-3小时。
合并提取液，在常压或减压加热浓缩成膏状，优选在减压条件下浓缩。
优选楹树浸膏的制备方法如下：称量粉碎的楹树茎皮药材，用80-95％乙醇回流2-4次，每次2-3小时；合并提取液，提取液经减压浓缩得到楹树(Albizia chinensis(Osbeck)Merr)浸膏。
(2)楹树浸膏进一步通过聚酰胺柱色谱，通过醇类溶剂梯度洗脱，精制纯化得到楹树提取物。
楹树浸膏以10-30％的乙醇溶解，优选20％的乙醇溶解。
聚酰胺吸附剂的用量为样品重量的25～80倍，优选35～40倍。
洗脱剂可以醇类与水的混合溶剂；优选的醇类溶剂为甲醇和乙醇，最优选醇类溶剂为乙醇。
洗脱溶剂的用量为聚酰胺干粉的体积3-10倍，优选洗脱剂用量为聚酰胺干粉的体积5-7倍。
依次用10-30％的乙醇、40-80％的乙醇进行梯度洗脱，40-80％的乙醇洗脱液减压回收得到楹树提取物。
优选的聚酰胺柱色谱纯化步骤包括：将楹树浸膏以10-30％的乙醇溶解后，加到30-40倍于浸膏重量的30～60目的聚酰胺柱上，依次用10-30％的乙醇、40-70％的乙醇进行梯度洗脱，洗脱溶剂的用量为5-7倍聚酰胺干粉的体积，浓缩40-70％的乙醇洗脱液得到楹树提取物。
本发明涉及了一种药物组合物，包括以本发明所述的方法提取的楹树提取物及药学上可接受的载体。
本发明还涉及含有作为活性成份的本发明提取物和常规药物赋形剂或辅剂的药物组合物。通常本发明药物组合物含有0.1～95％重量的本发明提取物。
本发明还提供一种药物组合物，它包括药物有效剂量的，作为活性成分的如本发明方法提取的楹树提取物和/或楹树及药学上可接受的载体。
本发明提取物的药物组合物可根据本领域公知的方法制备。用于此目的时，如果需要，可将本发明提取物与一种或多种固体或液体药物赋形剂和/或辅剂结合，制成可作为人药或兽药使用的适当的施用形式或剂量形式。
本发明提取物或含有它的药物组合物可以单位剂量形式给药，给药途径可为肠道或非肠道，如口服、静脉注射、肌肉注射、皮下注射、腹腔注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、阴道、直肠等，优选口服给药。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等。固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等；半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明提取物可以制成普通制剂、也可以是缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
为了将单位给药剂型制成片剂，可以广泛使用本领域公知的各种赋形剂，包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等；湿润剂可以是水、乙醇、异丙醇等；粘合剂可以是，淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯毗咯烷酮、聚乙二丙醇等；崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯毗咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与构椽酸、碳酸钙、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠；润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片，例如糖包衣片、薄膜包衣片、肠溶包衣片，或双层片和多层片。
为了将给药单元制成丸剂，可以广泛使用本领域公知的各种载体。关于载体的例子是，例如稀释剂与吸收剂，如葡萄糖、乳糖、淀粉、可可脂、氢化植物油、聚乙烯吡咯烷酮、月桂酸聚乙二醇甘油酯、高岭土、滑石粉等；粘合剂，如阿拉伯胶、黄菩胶、明胶、乙醇、蜂蜜、液糖、米糊或面糊等；崩解剂，如琼脂粉、干燥淀粉、海藻酸盐、十二烷基磺酸钠、甲基纤维素、乙基纤维素等。
为了将给药单元制成栓剂，可以广泛使用本领域公知的各种载体。关于载体的例子是，例如聚乙二醇、卵磷脂、可可脂、高级醇、高级醇的酯、明胶、半合成甘油酯等。
为了将给药单元制成胶囊，将有效成分本发明提取物与上述的各种载体混合，并将由此得到的混合物置于硬的明胶胶囊或软胶囊中。也可将有效成分本发明提取物制成微囊剂，混悬于水性介质中形成混悬剂，亦可装入硬胶囊中或制成注射剂应用。
例如，将本发明提取物制成注射用制剂，如溶液剂、混悬剂溶液剂、乳剂、冻干粉针剂，这种制剂可以是含水或非水的，可含一种和/或多种药效学上可接受的载体、稀释剂、粘合剂、润滑剂、防腐剂、表面活性剂或分散剂。如稀释剂可选自水、乙醇、聚乙二醇、1，3-丙二醇、乙氧基化的异硬脂醇、多氧化的异硬脂醇、聚氧乙烯山梨醇脂肪酸酯等。另外，为了制备等渗注射液，可以向注射用制剂中添加适量的氯化钠、葡萄糖或甘油，此外，还可以添加常规的助溶剂、缓冲剂、pH调节剂等。这些辅料是本领域常用的。
此外，如需要，也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂、甜味剂或其它材料。
为达到用药目的，增强治疗效果，本发明的药物或药物组合物可用任何公知的给药方法给药。
本发明提取物药物组合物的给药剂量取决于许多因素，例如所要预防或治疗疾病的性质和严重程度，患者或动物的性别、年龄、体重、性格及个体反应，给药途径、给药次数、治疗目的，因此本发明的治疗剂量可以有大范围的变化。一般来讲，本发明中药学成分的使用剂量是本领域技术人员公知的。可以根据本发明提取物组合物中最后的制剂中所含有的实际药物数量，加以适当的调整，以达到其治疗有效量的要求，完成本发明的预防或治疗目的。本发明提取物的每天的合适剂量范围本发明的提取物的用量为0.001～150mg/Kg体重，优选为0.1～100mg/Kg体重，更优选为1～60mg/Kg体重，最优选为2～50mg/Kg体重。上述剂量可以单一剂量形式或分成几个，例如二、三或四个剂量形式给药这受限于给药医生的临床经验以及包括运用其它治疗手段的给药方案。每一种治疗所需总剂量可分成多次或按一次剂量给药。本发明的提取物或组合物可单独服用，或与其他治疗药物或对症药物合并使用并调整剂量。
本发明通过楹树提取物对胃H+/K+-ATP酶抑制活性和对幽门结扎致大鼠胃溃疡的作用的研究，证明，楹树提取物具有显著的抗胃溃疡作用，其机理是通过抑制H+/K+-ATP酶活性。
有益技术效果
本发明楹树提取物作用物质基础和作用机理明确，制备工艺简单，适合工业化生产。
为治疗胃溃疡以及慢性胃炎的提供了一种新的药物。
附图说明
图1、楹树提取物的制备实施例1的流程图。
具体实施方式
下面的实施例及药物活性实验用来进一步说明本发明，实施例仅用于说明，不能限制本发明的范围。
实施例1 楹树提取物的制备方法
称取楹树茎皮粗粉2Kg，用6倍体积的95％乙醇回流三次，每次3小时；提取液经减压浓缩得浸膏270g，再以20％的乙醇溶解，加到6500ml的聚酰胺(30～60目)柱上，依次用6L 20％的乙醇、7L 60％的乙醇进行梯度洗脱，浓缩60％的乙醇洗脱液至干，即得到楹树提取物20g。
药理实验
试验例1 楹树提取物抑制胃H+/K+-ATP酶活性
实验方法：
H+/K+-ATP酶活性测定：将纯化的猪胃黏膜囊泡加缓冲液稀释，加药后在37℃水浴温孵20min，加入20mg/kg ATP继续温孵30min，加入10％TCA终止反应，6000rpm离心10min。取定量上清液用定磷试剂盒于660nm测定H+/K+-ATP酶水解释放的无机磷含量。计算酶活力。
结果：
数据见表1。楹树提取物(1和10mg/L)对猪胃H+/K+-ATP酶活性的抑制率分别为28％和73％。提示楹树提取物对H+/K+-ATP酶活性具有较强的抑制作用。
表1 楹树提取物对猪胃H+/K+-ATP酶活性的影响
| 浓度(mg/L) | 抑制率(％) |
| 1 | 28 |
| 10 | 73 |
试验例2 楹树提取物对幽门结扎致大鼠胃溃疡的保护作用
实验方法：
取禁食48小时的雄性大鼠，随机分为3组。乙醚麻醉下行幽门结扎术，术时经十二指肠给予100和500mg/kg的楹树提取物，对照组大鼠给予生理盐水。术后20小时处死动物，取出胃，计前胃部溃疡数。结果用One-way ANOVA进行差异显著性检验。
结果：
数据见表2。楹树提取物在100和500mg/kg剂量下对幽门结扎致大鼠胃溃疡的抑制率分别为43％和86％(p＜0.05)。提示楹树提取物对幽门结扎溃疡模型有很好的保护作用。
表2 楹树提取物对大鼠幽门结扎致溃疡模型的影响
| 剂量(mg/kg) | 溃疡减少率(％) |
| 100 | 43 |
| 500 | 86 |
Claims (12)
1.一种楹树(Albizia chinensis(Osbeck)Merr)提取物的制备方法，其特征在于，包括如下步骤：
A.楹树(Albizia chinensis(Osbeck)Merr)药材采用溶剂提取，
B.通过聚酰胺柱色谱，溶剂梯度洗脱精制纯化得到楹树提取物。
2.根据权利要求1所述的制备方法，其特征在于，步骤A中所述的溶剂选自醇类或水与醇类的混合溶剂。
3.根据权利要求2所述的制备方法，其特征在于，步骤A包括如下步骤：粉碎楹树(Albizia chinensis(Osbeck)Merr)茎皮，以每公斤药材4-10升的60-95％乙醇回流2-4次，每次2-3小时；合并提取液，提取液经减压浓缩得到楹树(Albizia chinensis(Osbeck)Merr)浸膏。
4.根据权利要求1所述的制备方法，其特征在于，步骤B为将步骤A中获得的楹树浸膏以10-30％的乙醇溶解后，加到30-40倍于浸膏重量的30～90目的聚酰胺柱上，依次用10-30％的乙醇、40-80％的乙醇进行梯度洗脱，洗脱溶剂的用量为5-7倍30～90目聚酰胺干粉的体积，浓缩40-80％的乙醇洗脱液得到所述的楹树提取物。
5.权利要求1-4中任一项制备的楹树(Albizia chinensis(Osbeck)Merr)提取物。
6.一种药物组合物，其特征在于，含有作为有效成分的权利要求5的楹树(Albizia chinensis(Osbeck)Merr)提取物，及药学上可接受的载体。
7.权利要求5的楹树(Albizia chinensis(Osbeck)Merr)提取物作为质子泵抑制剂的应用。
8.权利要求5的楹树(Albizia chinensis(Osbeck)Merr)提取物在制备治疗酸相关性疾病药物中的应用。
9.根据权利要求8的应用，其特征在于，所述的酸相关性疾病选自胃溃疡、慢性胃炎。
10.楹树(Albizia chinensis(Osbeck)Merr)作为质子泵抑制剂的应用。
11.楹树(Albizia chinensis(Osbeck)Merr)在制备治疗酸相关性疾病药物中的应用。
12.根据权利要求11的应用，其特征在于，所述的酸相关性疾病选自胃溃疡、慢性胃炎。
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110326361.1A CN103054932B (zh) | 2011-10-24 | 2011-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
| RU2014116582A RU2651750C2 (ru) | 2011-10-24 | 2012-10-24 | Применение экстракта albizzia chinensis для получения лекарственного средства для лечения язвы желудка |
| EP12843553.4A EP2772264B8 (en) | 2011-10-24 | 2012-10-24 | Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer |
| PCT/CN2012/083458 WO2013060275A1 (zh) | 2011-10-24 | 2012-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
| US14/353,926 US9393277B2 (en) | 2011-10-24 | 2012-10-24 | Application of Albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer |
| CN201280052172.2A CN103906525B (zh) | 2011-10-24 | 2012-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
| JP2014537478A JP6076361B2 (ja) | 2011-10-24 | 2012-10-24 | 胃潰瘍の治療用医薬の調製におけるＡｌｂｉｚｚｉａｃｈｉｎｅｎｓｉｓ抽出物の応用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110326361.1A CN103054932B (zh) | 2011-10-24 | 2011-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103054932A true CN103054932A (zh) | 2013-04-24 |
| CN103054932B CN103054932B (zh) | 2018-04-27 |
Family
ID=48098027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110326361.1A Active CN103054932B (zh) | 2011-10-24 | 2011-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
| CN201280052172.2A Active CN103906525B (zh) | 2011-10-24 | 2012-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280052172.2A Active CN103906525B (zh) | 2011-10-24 | 2012-10-24 | 楹树提取物在制备治疗胃溃疡药物中的应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9393277B2 (zh) |
| EP (1) | EP2772264B8 (zh) |
| JP (1) | JP6076361B2 (zh) |
| CN (2) | CN103054932B (zh) |
| RU (1) | RU2651750C2 (zh) |
| WO (1) | WO2013060275A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223836A (zh) * | 2018-10-16 | 2019-01-18 | 徐州工程学院 | 一种球孢虫草提取物及其制备方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10309838B2 (en) * | 2016-09-08 | 2019-06-04 | Qualcomm Incorporated | Temporal temperature sensor position offset error correction |
| CN114656575B (zh) * | 2022-03-07 | 2022-12-06 | 中国科学院上海药物研究所 | 一种合欢花非均一多糖，其制备方法及用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766676A (zh) * | 2008-12-30 | 2010-07-07 | 中国医学科学院药物研究所 | 一种楹树提取物、其制备方法及其组合物与用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167787B (zh) * | 2007-10-17 | 2011-06-22 | 江南大学 | 抑制血管生成的合欢属植物提取物的组合物及其制备和应用 |
| CN101239093A (zh) * | 2008-03-10 | 2008-08-13 | 江南大学 | 合欢皮中具有抑制血管生成作用的活性成份及其制备方法和应用 |
-
2011
- 2011-10-24 CN CN201110326361.1A patent/CN103054932B/zh active Active
-
2012
- 2012-10-24 US US14/353,926 patent/US9393277B2/en active Active
- 2012-10-24 EP EP12843553.4A patent/EP2772264B8/en active Active
- 2012-10-24 RU RU2014116582A patent/RU2651750C2/ru active
- 2012-10-24 CN CN201280052172.2A patent/CN103906525B/zh active Active
- 2012-10-24 JP JP2014537478A patent/JP6076361B2/ja active Active
- 2012-10-24 WO PCT/CN2012/083458 patent/WO2013060275A1/zh active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766676A (zh) * | 2008-12-30 | 2010-07-07 | 中国医学科学院药物研究所 | 一种楹树提取物、其制备方法及其组合物与用途 |
Non-Patent Citations (3)
| Title |
|---|
| 刘洪妹: "质子泵抑制剂的药理作用及临床应用", 《解放军医药杂志》 * |
| 刘锐等: "楹树叶的化学成分", 《中国中药杂志》 * |
| 蔡行平等: "消化性溃疡的中医辨治方法探讨", 《新中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223836A (zh) * | 2018-10-16 | 2019-01-18 | 徐州工程学院 | 一种球孢虫草提取物及其制备方法 |
| CN109223836B (zh) * | 2018-10-16 | 2021-10-01 | 徐州工程学院 | 一种球孢虫草提取物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013060275A1 (zh) | 2013-05-02 |
| EP2772264A4 (en) | 2015-07-01 |
| CN103906525A (zh) | 2014-07-02 |
| EP2772264A1 (en) | 2014-09-03 |
| RU2651750C2 (ru) | 2018-04-23 |
| JP2014530884A (ja) | 2014-11-20 |
| RU2014116582A (ru) | 2015-12-10 |
| JP6076361B2 (ja) | 2017-02-08 |
| EP2772264B1 (en) | 2022-08-03 |
| US9393277B2 (en) | 2016-07-19 |
| CN103054932B (zh) | 2018-04-27 |
| EP2772264B8 (en) | 2022-10-19 |
| CN103906525B (zh) | 2017-12-22 |
| US20150010664A1 (en) | 2015-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100415280C (zh) | 一种治疗荨麻疹的中药制剂 | |
| CN104138550A (zh) | 一种治疗消化性溃疡药物的制备方法 | |
| CN102526164A (zh) | 防治胰岛素抵抗及其相关代谢综合征的中药组合物 | |
| CN103054932B (zh) | 楹树提取物在制备治疗胃溃疡药物中的应用 | |
| CN100352831C (zh) | 地榆总皂苷提取物及其制备方法和用途 | |
| JP2014208620A (ja) | 抗肥満剤 | |
| CN101766676B (zh) | 一种楹树提取物、其制备方法及其组合物与用途 | |
| CN101433598A (zh) | 虎杖预防和治疗胰岛素抵抗及其相关代谢性疾病的用途 | |
| CN101164571A (zh) | 栀子有效部位在治疗老年期痴呆中的用途 | |
| CN101428055A (zh) | 红景天属植物预防和治疗糖尿病和肥胖症药物的用途 | |
| CN108892651B (zh) | 一种混源萜二聚体类化合物及其药物组合物和其应用 | |
| CN101396435A (zh) | 一种治疗胃病的中药及其制备方法和应用 | |
| CN107865932B (zh) | 一种具有减肥功效的中药组合物 | |
| CN104138553A (zh) | 一种治疗消化性溃疡的药物组合物 | |
| CN102058676B (zh) | 一种治疗溃疡性结肠炎的中药提取物、其药物组合物及其制备方法 | |
| CN109453249B (zh) | 防治药物性肝损伤的药物组合物及不同剂型的制备方法 | |
| CN101940585A (zh) | 一种以荭草素-2"-O-β-L-半乳糖苷为主要成分的组合物及其用途 | |
| CN107375409B (zh) | 龙须藤多甲氧基总黄酮治疗和预防胃溃疡的应用 | |
| CN104739918A (zh) | 九龙藤总黄酮在制备防治冠心病药物中的应用 | |
| CN102228665B (zh) | 来自松花粉与姜黄的组合物及其制备方法和该组合物在制备保护胃粘膜的药物中的应用 | |
| CN116196364A (zh) | 番红花废弃物的提取物在制备预防和/或治疗肠道炎症疾病药物中的应用 | |
| CN1425384A (zh) | 远志总皂苷在制备促进胃肠蠕动药物中的应用 | |
| CN110548086A (zh) | 一种止咳复方制剂及其制备方法 | |
| CN101890036B (zh) | 黄芪苷的用途 | |
| CN112426478A (zh) | 一种治疗肠癌的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |